Microsoft Azure AI solution integration… ‘World without disease’ vision declaration ceremony scheduled for the first half of the year
▲Seegene CEO Cheon Jong-yoon (right) and Microsoft Global Health and Life Sciences Division head Elena Bonfiglioli attended the agreement ceremony for strategic cooperation in technology sharing projects held in London, England on the 23rd (local time) and signed the MOU. We are taking a commemorative photo afterwards. (Photo provided by Seegene)
Seegene announced on the 24th that it would cooperate with Microsoft to promote technology sharing projects to realize the vision of a ‘world without disease.’
Through collaboration with Microsoft, Seegene plans to share syndromic quantitative PCR technology with several companies and lead cross-industry innovation in the field of molecular diagnostics. In addition, the goal is to expand the number of companies participating in the global consortium to provide optimal solutions to countries around the world and to effectively respond to future pandemics to create a ‘world free from all diseases.’
Seegene collaborates with Microsoft’s global healthcare team to achieve its vision and connect with partners. In addition, we will jointly participate in the Technology Sharing Project’s annual symposium and other major events to connect current and potential partners. We plan to hold a declaration ceremony for the scientific community and other partners participating in technology sharing projects in the first half of this year.
The technology sharing project is a global strategy pursued by Seegene to create a disease-free world. Scientists and experts around the world use Seegene’s developer automation system (SGDDS) to directly develop diagnostic reagents for various diseases in humans, animals, and plants. Seegene plans to form a global consortium partnership with about 100 companies representing each country and share Seegene’s syndromic quantitative PCR technology. Based on this, partner companies in each country plan to establish local companies dedicated to product development, production, and sales.
Seegene’s SGDDS is applied to a cloud computing platform including Microsoft Azure Open AI Service. The massive data generated by SGDDS is used to process data interaction and analysis environments for researchers. This is expected to protect sensitive personal information by providing a trustworthy research environment (TRE) and help comply with information regulations in each country.
In addition, Microsoft Fabric, an AI-based single analysis platform that allows everyone to access and manage data, will also be introduced. Seegene will have access to data integration, data engineering, data science, data monitoring, real-time analytics and business intelligence capabilities. In addition, we plan to provide integrated AI-based services through Microsoft 365 Copilot (Copilot for Microsoft 365).
Seegene CEO Cheon Jong-yoon said, “Through strategic collaboration with Microsoft, we have been able to build a more systematic technology sharing business model. We expect that the synergy effect achieved through cooperation between the two companies will open the way to a world free from all diseases.” He said.
Elena Bonfiglioli, head of Microsoft’s global health and life sciences division, said, “In addition to working together for Seegene’s digital transformation, we will work together to discover global partners and further strengthen the healthcare ecosystem.”